VentriPoint Diagnostics (CVE:VPT) Stock Price Down 13.6% – What’s Next?

VentriPoint Diagnostics Ltd. (CVE:VPT) shares dropped 13.6% during mid-day trading on Tuesday . The company traded as low as C$0.10 and last traded at C$0.10. Approximately 570,496 shares were traded during mid-day trading, an increase of 339% from the average session volume of 129,831 shares. The stock had previously closed at C$0.11.

VentriPoint Diagnostics Stock Down 13.6%

The company has a quick ratio of 6.67, a current ratio of 0.08 and a debt-to-equity ratio of -63.20. The business has a 50-day simple moving average of C$0.13 and a two-hundred day simple moving average of C$0.12. The stock has a market capitalization of C$17.83 million, a P/E ratio of -4.75 and a beta of -0.29.

VentriPoint Diagnostics Company Profile

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.